Company
Description
We are a clinical stage immunotherapy biopharmaceutical company in China focused on the innovation, development and clinical translation of gene and cell immunotherapies for solid tumours and haematological malignancies. Leveraging multiple proprietary cell engineering platforms, we are currently advancing eight pipelines, investigating the emerging field of immune cell therapies across multiple cancer types.To support our R&D roadmap and clinical translation, we have established multiple R&D centres and manufacturing facilities in the U.S. and China. These facilities provide the foundation for efficient product development, paving the way for our future advancements in the cell and gene therapy field.
